These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 27002448)

  • 1. Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial.
    Samadder NJ; Neklason DW; Boucher KM; Byrne KR; Kanth P; Samowitz W; Jones D; Tavtigian SV; Done MW; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Davis R; Topham MK; Lynch P; Strait E; McKinnon W; Burt RW; Kuwada SK
    JAMA; 2016 Mar 22-29; 315(12):1266-75. PubMed ID: 27002448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial.
    Samadder NJ; Kuwada SK; Boucher KM; Byrne K; Kanth P; Samowitz W; Jones D; Tavtigian SV; Westover M; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Burt RW; Neklason DW
    JAMA Oncol; 2018 May; 4(5):671-677. PubMed ID: 29423501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
    Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
    BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis.
    Samadder NJ; Foster N; McMurray RP; Burke CA; Stoffel E; Kanth P; Das R; Cruz-Correa M; Vilar E; Mankaney G; Buttar N; Thirumurthi S; Turgeon DK; Sossenheimer M; Westover M; Richmond E; Umar A; Della'Zanna G; Rodriguez LM; Szabo E; Zahrieh D; Limburg PJ
    Gut; 2023 Feb; 72(2):256-263. PubMed ID: 35636921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia.
    Delker DA; Wood AC; Snow AK; Samadder NJ; Samowitz WS; Affolter KE; Boucher KM; Pappas LM; Stijleman IJ; Kanth P; Byrne KR; Burt RW; Bernard PS; Neklason DW
    Cancer Prev Res (Phila); 2018 Jan; 11(1):4-15. PubMed ID: 29109117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variables affecting penetrance of gastric and duodenal phenotype in familial adenomatous polyposis patients.
    Sample DC; Samadder NJ; Pappas LM; Boucher KM; Samowitz WS; Berry T; Westover M; Nathan D; Kanth P; Byrne KR; Burt RW; Neklason DW
    BMC Gastroenterol; 2018 Jul; 18(1):115. PubMed ID: 30012100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP).
    Ulusan AM; Rajendran P; Dashwood WM; Yavuz OF; Kapoor S; Gustafson TA; Savage MI; Brown PH; Sei S; Mohammed A; Vilar E; Dashwood RH
    Cancer Prev Res (Phila); 2021 Mar; 14(3):325-336. PubMed ID: 33277315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial.
    van Heumen BW; Roelofs HM; Vink-Börger ME; Dekker E; Mathus-Vliegen EM; Dees J; Koornstra JJ; Langers AM; Nagtegaal ID; Kampman E; Peters WH; Nagengast FM
    Orphanet J Rare Dis; 2013 Aug; 8():118. PubMed ID: 23919274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Metformin in Treatment of Adenomas in Patients with Familial Adenomatous Polyposis.
    Park JJ; Kim BC; Hong SP; Seo Y; Lee HS; Park YS; Na SY; Park SC; Park J; Kim JH; Moon CM; Huh KC; Park SJ; Cheon JH; Kim WH; Kim TI
    Cancer Prev Res (Phila); 2021 May; 14(5):563-572. PubMed ID: 33509804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis.
    Bowen CM; Walter L; Borras E; Wu W; Ozcan Z; Chang K; Bommi PV; Taggart MW; Thirumurthi S; Lynch PM; Reyes-Uribe L; Scheet PA; Sinha KM; Vilar E
    Cancer Prev Res (Phila); 2021 Sep; 14(9):851-862. PubMed ID: 34266857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis.
    Nugent KP; Farmer KC; Spigelman AD; Williams CB; Phillips RK
    Br J Surg; 1993 Dec; 80(12):1618-9. PubMed ID: 8298943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulindac for periampullary polyps in FAP patients.
    Richard CS; Berk T; Bapat BV; Haber G; Cohen Z; Gallinger S
    Int J Colorectal Dis; 1997; 12(1):14-8. PubMed ID: 9112144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulindac and Erlotinib for Familial Adenomatous Polyposis.
    Matuchansky C
    JAMA; 2016 Aug; 316(5):544-5. PubMed ID: 27483077
    [No Abstract]   [Full Text] [Related]  

  • 14. Sulindac and Erlotinib for Familial Adenomatous Polyposis--Reply.
    Samadder NJ; Neklason DW; Burt RW
    JAMA; 2016 Aug; 316(5):545. PubMed ID: 27483082
    [No Abstract]   [Full Text] [Related]  

  • 15. Prospective randomized study of sulindac versus calcium and calciferol for upper gastrointestinal polyps in familial adenomatous polyposis.
    Seow-Choen F; Vijayan V; Keng V
    Br J Surg; 1996 Dec; 83(12):1763-6. PubMed ID: 9038563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study.
    Cruz-Correa M; Hylind LM; Romans KE; Booker SV; Giardiello FM
    Gastroenterology; 2002 Mar; 122(3):641-5. PubMed ID: 11874996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Predicators of Duodenal Familial Adenomatous Polyposis Chemoprevention: Do Chemopreventive Drugs Hit Their Presumed Molecular Targets?
    Shureiqi I
    Cancer Prev Res (Phila); 2018 Jan; 11(1):1-3. PubMed ID: 29263155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
    Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
    Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, placebo-controlled trial of gastric acid-lowering therapy on duodenal polyposis and relative adduct labeling in familial adenomatous polyposis.
    Wallace MH; Forbes A; Beveridge IG; Spigelman AD; Hewer A; Venitt S; Phillips RK
    Dis Colon Rectum; 2001 Nov; 44(11):1585-9. PubMed ID: 11711728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of chromoendoscopy for surveillance of the duodenum in patients with MUTYH-associated polyposis and familial adenomatous polyposis.
    Hurley JJ; Thomas LE; Walton SJ; Thomas-Gibson S; Haycock A; Suzuki N; Mort M; Williams G; Morgan M; Clark SK; Sampson JR; Dolwani S
    Gastrointest Endosc; 2018 Oct; 88(4):665-673. PubMed ID: 29702101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.